NOVO.B.DK

462.75

-0.53%↓

COLO.B.DK

693.4

-1.08%↓

GMAB.DK

1,278

-0.23%↓

HLUNB.DK

31.88

+0.57%↑

AMBUB.DK

114.3

0%↓

NOVO.B.DK

462.75

-0.53%↓

COLO.B.DK

693.4

-1.08%↓

GMAB.DK

1,278

-0.23%↓

HLUNB.DK

31.88

+0.57%↑

AMBUB.DK

114.3

0%↓

NOVO.B.DK

462.75

-0.53%↓

COLO.B.DK

693.4

-1.08%↓

GMAB.DK

1,278

-0.23%↓

HLUNB.DK

31.88

+0.57%↑

AMBUB.DK

114.3

0%↓

NOVO.B.DK

462.75

-0.53%↓

COLO.B.DK

693.4

-1.08%↓

GMAB.DK

1,278

-0.23%↓

HLUNB.DK

31.88

+0.57%↑

AMBUB.DK

114.3

0%↓

NOVO.B.DK

462.75

-0.53%↓

COLO.B.DK

693.4

-1.08%↓

GMAB.DK

1,278

-0.23%↓

HLUNB.DK

31.88

+0.57%↑

AMBUB.DK

114.3

0%↓

Search

Zealand Pharma A-S

Deschisă

459.2 0.48

Rezumat

Modificarea prețului

24h

Curent

Minim

449

Maxim

480.8

Indicatori cheie

By Trading Economics

Venit

-25M

-291M

Vânzări

4.6M

9.1M

EPS

-4.12

Marjă de profit

-3,213.715

Angajați

335

EBITDA

8.1M

-253M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+25.15% upside

Dividende

By Dow Jones

Următoarele câștiguri

15 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-13B

37B

Deschiderea anterioară

458.72

Închiderea anterioară

459.2

Zealand Pharma A-S Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 mar. 2025, 09:23 UTC

Principalele dinamici ale pieței

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

20 dec. 2024, 09:22 UTC

Principalele dinamici ale pieței

Zealand Pharma Shares Fall After FDA Pushes Back Bowel-Disease Drug

12 mar. 2025, 16:34 UTC

Top știri

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12 mar. 2025, 08:18 UTC

Market Talk

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

Comparație

Modificare preț

Zealand Pharma A-S Așteptări

Obiectiv de preț

By TipRanks

25.15% sus

Prognoză pe 12 luni

Medie 270.582 DKK  25.15%

Maxim 270.568 DKK

Minim 270.568 DKK

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruZealand Pharma A-S - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

0

Cumpărare

1

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.